disorder

(redirected from Hypoactive sexual desire disorder)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.
Related to Hypoactive sexual desire disorder: Sexual aversion disorder, HSDD

disorder

a disturbance of public order or peace. Its existence may trigger extended police powers.
Mentioned in ?
References in periodicals archive ?
Global Hypoactive Sexual Desire Disorder Treatment Market Portraiture
Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Analysis Report, 2017-2019 & 2027
A standardized diagnostic interview for hypoactive sexual desire disorder in women: Standard operating procedure (SOP Part 2).
Female sexual dysfunction
Simon, and Irwin Goldstein, "Current Outlook for Testosterone in the Management of Hypoactive Sexual Desire Disorder in Postmenopausal Women," Journal of Sexual Medicine 5, suppl.
Reconsidering Asexuality and Its Radical Potential
But, when sexual fantasies or thoughts and desire for sexual activity are persistently or recurrently reduced or absent and cause distress or interpersonal difficulties, the problem is known as hypoactive sexual desire disorder or inhibited sexual desire disorder.
Sexual dysfunction
Relationship between hypoactive sexual desire disorder and aging.
Relationship between loss of libido and signs and symptoms of depression in a sample of Puerto Rican middle-aged women
M2 PHARMA-April 15, 2019-Sprout Pharmaceuticals announces revised label for Addyi for the treatment of hypoactive sexual desire disorder in women
Sprout Pharmaceuticals announces revised label for Addyi for the treatment of hypoactive sexual desire disorder in women
Hypoactive sexual desire disorder (HSDD) is believed to be the most common of the various FSDs.
Hypoactive Sexual Desire Disorder (HSDD): Communication and Counseling
Open-label extension study of flibanserin in women with hypoactive sexual desire disorder. J Sex Med.
SEXUAL ACTIVITY IN PATIENTS WITH CARDIAC DISEASES
She speculated that flibanserin, a selective agonist for 5-HTlA and an antagonist for 5-HT2A receptors approved in 2015 by the Food and Drug Administration for premenopausal women with hypoactive sexual desire disorder, "will start making its way into the general population," said Dr.
Ask service members and veterans about sexual health
About 40% of women experience low desire, and 6%-10% meet criteria for the diagnosis of hypoactive sexual desire disorder (HSDD).
FDA made the right call
After a five-year battle for approval, on August 18th, the agency succumbed to a relentless and clever public relations campaign and approved flibanserin, the first drug to treat hypoactive sexual desire disorder (HSDD) in women.
Flibanserin: the FDA's approval is bad science and bad precedent

Legal browser ?
Full browser ?